NCT05912114 is a NA clinical trial of Mannitol in Bowel Cleansing; Good Taste, sponsored by Ningbo No. 1 Hospital.

Who is sponsoring NCT05912114?

NCT05912114 is sponsored by Ningbo No. 1 Hospital.

What drugs are being tested in NCT05912114?

Interventions in NCT05912114: Mannitol, Polyethylene glycol electrolyte.

What condition does NCT05912114 study?

NCT05912114 studies Bowel Cleansing; Good Taste.

Is NCT05912114 still recruiting?

NCT05912114 is currently status unknown. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT05912114

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effectiveness of Mannitol Versus Polyethylene Glycol Electrolyte Dispersion as a Salve for Patients With Inadequate Bowel Preparation: a Randomized Controlled Clinical Trial

Status unknown NA Last updated 22 June 2023

What this trial tests

NA trial testing Mannitol in Bowel Cleansing; Good Taste in 134 participants. Status unknown.

Timeline

10 June 2023

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Ningbo No. 1 Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	134
Start date	10 June 2023
Primary completion	31 December 2024
Estimated completion	31 December 2024
Sites	1 location across China

Drugs / interventions tested

Mannitol (Mannitol) — full drug profile →
Polyethylene glycol electrolyte

Conditions studied

Bowel Cleansing; Good Taste — all drugs for Bowel Cleansing; Good Taste →

Sponsor

Ningbo No. 1 Hospital

Who can join

Adults 18 to 75, any sex, with Bowel Cleansing; Good Taste. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

For patients with inadequate bowel preparation, current guidelines recommend either remedial measures or rescheduling the endoscopy, but previous surveys have found that approximately 30% of patients do not follow medical advice to reschedule the examination if it is rescheduled, while those who take remedial measures on the same day are more compliant, so remedial measures may be a better option than rescheduling the examination. As for the remedy regimen, it has been demonstrated that oral PEG is superior to the enema regimen in terms of bowel cleansing, but PEG is very resistant to be taken by most patients due to its poor taste and the larger doses required, resulting in poor bowel preparation and poor compliance. In contrast, oral mannitol has the advantages of small dose and good taste, and patient compliance may be higher.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Comparing the efficacy of mannitol and polyethylene glycol in treating patients with poor bowel preparation: a randomized controlled clinical study.
Zheng S, Xu Z, Deng F, Wang S, et al · · 2025 · PMID 41444456 · DOI 10.1007/s10151-025-03243-y

Verify or expand the search:

Other trials of Mannitol

Trials testing the same drug.

NCT07433023 — tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy · Phase 2 · not yet recruiting
NCT06914310 — Memantine as an Additive Therapy in Patients With Traumatic Brain Injury · Phase 2, PHASE3 · not yet recruiting
NCT06473779 — Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remiss · Phase 3 · active not recruiting
NCT06540352 — A Study to Select the Dose and Evaluate the Effectiveness and Safety of the Drug Refralon®, Tablets, 1 mg for Long-term · Phase 2 · active not recruiting
NCT06841406 — Budesonide as a Treatment for Functional Dyspepsia · Phase 4 · recruiting

Other Ningbo No. 1 Hospital trials

Trials by the same sponsor.

NCT07181759 — Clinical Trial of VISOR vs fURS for Upper Urinary Tract Stone · NA · not yet recruiting
NCT07001865 — Metabolically Healthy Obesity Increases the Risks of MASLD and Hyperuricemia · enrolling by invitation
NCT06984510 — Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population · recruiting
NCT06905795 — Screening and Intervention of MASLD in Children · NA · active not recruiting
NCT06987760 — Comparing Different Diameter fURSs With Similar RESDs for the Treatment of Upper Urinary Tract Stones · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05912114 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ningbo No. 1 Hospital
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05912114.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing